Literature DB >> 21651439

The generic amyloid formation inhibition effect of a designed small aromatic β-breaking peptide.

Anat Frydman-Marom1, Ronit Shaltiel-Karyo, Sari Moshe, Ehud Gazit.   

Abstract

The development of generic inhibitors in order to control the formation of amyloid fibrils and early oligomers is still an unmet medical need. As it is hypothesized that amyloid assemblies represent a generic protein supramolecular structure of low free energy, targeting the key molecular recognition and self-assembly events may provide the route for the development of such potential therapeutic agents. We have previously demonstrated the ability of hybrid molecules composed of an aromatic moiety and the α-aminoisobutyric acid β-sheet breaker elements to act as excellent inhibitors of amyloid fibril formation. Specifically, the D-Trp-Aib was shown to be a superb inhibitor of the formation of Alzheimer's disease β-amyloid fibrils and oligomers both in vitro and in vivo. Here, we demonstrate that the rationally designed molecule has the generic ability to inhibit amyloid fibril formation by calcitonin, α-synuclein, and the islet amyloid polypeptide. Moreover, we demonstrate the inability of two modified peptides, D-Ala-Aib and D-Trp-Ala, to inhibit and disassemble amyloid fibril formation, a fact that provides an additional evidence for the suggested structural basis of the inhibitor activity. Taken together, we believe that the use of β-breaker elements combined with aromatic moiety may present a promising approach for the development of fibrillization inhibition drug candidate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21651439     DOI: 10.3109/13506129.2011.582902

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  14 in total

1.  Peptide Conjugates of Benzene Carboxylic Acids as Agonists and Antagonists of Amylin Aggregation.

Authors:  Adam A Profit; Jayson Vedad; Ruel Z B Desamero
Journal:  Bioconjug Chem       Date:  2017-01-27       Impact factor: 4.774

2.  Binding Modes of Phthalocyanines to Amyloid β Peptide and Their Effects on Amyloid Fibril Formation.

Authors:  Ariel A Valiente-Gabioud; Dietmar Riedel; Tiago F Outeiro; Mauricio A Menacho-Márquez; Christian Griesinger; Claudio O Fernández
Journal:  Biophys J       Date:  2018-03-13       Impact factor: 4.033

3.  Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation.

Authors:  Yuan Zheng; Jing Qu; Fenqin Xue; Yan Zheng; Bo Yang; Yongchang Chang; Hui Yang; Jianliang Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2018-03-06       Impact factor: 8.886

4.  Rationally designed peptide-based inhibitor of Aβ42 fibril formation and toxicity: a potential therapeutic strategy for Alzheimer's disease.

Authors:  John R Horsley; Blagojce Jovcevski; Kate L Wegener; Jingxian Yu; Tara L Pukala; Andrew D Abell
Journal:  Biochem J       Date:  2020-06-12       Impact factor: 3.857

5.  Role of Tyr-39 for the Structural Features of α-Synuclein and for the Interaction with a Strong Modulator of Its Amyloid Assembly.

Authors:  Oscar Palomino-Hernandez; Fiamma A Buratti; Pamela S Sacco; Giulia Rossetti; Paolo Carloni; Claudio O Fernandez
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

6.  Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model.

Authors:  Xiaoxi Ren; Yun Zhao; Fenqin Xue; Yan Zheng; Haixia Huang; Wei Wang; Yongchang Chang; Hui Yang; Jianliang Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-23       Impact factor: 8.886

7.  Antioxidant Berberine-Derivative Inhibits Multifaceted Amyloid Toxicity.

Authors:  Kolla Rajasekhar; Sourav Samanta; Vardhaman Bagoband; N Arul Murugan; Thimmaiah Govindaraju
Journal:  iScience       Date:  2020-03-25

8.  A unified conformational selection and induced fit approach to protein-peptide docking.

Authors:  Mikael Trellet; Adrien S J Melquiond; Alexandre M J J Bonvin
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

9.  Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.

Authors:  Angel Agis-Torres; Monica Sölhuber; Maria Fernandez; J M Sanchez-Montero
Journal:  Curr Neuropharmacol       Date:  2014-01       Impact factor: 7.363

10.  Automated Ex Situ Assays of Amyloid Formation on a Microfluidic Platform.

Authors:  Kadi-Liis Saar; Emma V Yates; Thomas Müller; Séverine Saunier; Christopher M Dobson; Tuomas P J Knowles
Journal:  Biophys J       Date:  2016-02-02       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.